Tuesday, 12 April 2016 10:31

Glaxo’s Potential Cure for “Bubble Boy Disease” One Step Closer

Written by 
Rate this item
(1 Vote)

Glaxo’s Potential Cure for “Bubble Boy Disease” One Step Closer

A potential cure for children born with a form of an extremely rare immune-system condition often referred to as “bubble-boy disease” has moved a step closer to approval after receiving the support of a European Union regulatory panel.

 

The treatment, which involves inserting a new gene into the patient’s stem cells, received a positive opinion from the European Medicines Agency’s advisory committee on Friday, paving the way for final approval in coming months.

It is aimed at children with a disease known as ADA-SCID, a rare condition in which a single genetic defect prevents sufferers from developing a robust immune system, leaving them very susceptible to infections. Without treatment, they rarely live for more than two years.

Currently, the best available option is a bone-marrow transplant, but success heavily depends on how well matched the donor is. For the one in four babies who have a well matched family member, a transplant can be an effective cure. But for the rest, success rates can be as low as 50%, according to Bobby Gaspar,professor of pediatrics and immunology at London’s Great Ormond Street Hospital.

The new therapy, called Strimvelis, was developed by a group of scientists and doctors based in Milan who have used it to treat 22 children over the past 14 years. All are still alive, most without needing any further treatment. In 2010, GlaxoSmithKline PLC struck a licensing deal for the rights to market the therapy.

If approved, it would be only the second gene therapy to be sold in Europe, after UniQure NV’s Glybera for a rare genetic condition in which the body can’t break down fat molecules. No gene therapies are approved for sale in the U.S.

The ADA-SCID gene therapy has moved at a cautious pace. Scientists tested an older form of gene therapy in children with the disease as early as 1990, but suffered a setback when, around 10 years later, several of those patients developed a leukemia-like condition.

“To be recognized as a licensed medicine shows gene therapy has come a long way forward,” Dr. Gaspar said.

One complication of administering Strimvelis: For now, it can be performed only in the Milan hospital where it was developed. The procedure involves removing some stem cells from the patient, applying the gene therapy outside the body and then reinjecting them, all of which must be done in quick succession to keep within the short “shelf life” of stem cells.

Parents will probably be willing to take their babies to Milan for treatment if it is considered the best option: Children from as far away as the U.S. and the Middle East came to Italy to take part in the clinical trial, according to Martin Andrews, head of the company’s rare-disease unit. Still, Glaxo aims to eventually make the therapy available in several “hubs,” and is working on methods to increase the shelf life of stem cells so that the procedure could be done remotely, by sending the child’s stem cells to a central facility for the gene therapy, he said. Glaxo also plans to seek approval from America’s Food and Drug Administration in 2017.

While Strimvelis is unlikely to move the needle for Glaxo in terms of revenue—around 14 babies are born with the condition every year in Europe—the company is betting that the technology can be used as the basis for several new treatments, Mr. Andrews said.

Rare diseases have drawn increasing interest from drugmakers in the past few years because the industry can command high prices for effective treatments in diseases with few other available therapies.

“If efficacy is demonstrated, payers are willing to reimburse [the companies],” said Mladen Tomich, head analyst for rare diseases at health-care consultancy Decision Resources Group. “While the price tag is high the overall expenditures are still limited due to the small patient population.”

Mr. Andrews didn’t disclose Glaxo’s pricing plans for the treatment but said it was considering flexible pricing models, including amortizing the payment over several years.

 

 

Read 512325 times Last modified on Tuesday, 12 April 2016 10:52

27749 comments

  • Comment Link Earlie Pajak Wednesday, 18 October 2017 11:08 posted by Earlie Pajak

    wonderful points altogether, you just gained a emblem new reader. What might you suggest in regards to your put up that you made some days in the past? Any certain?

  • Comment Link José Wilame Araújo Rodrigues Wednesday, 18 October 2017 11:05 posted by José Wilame Araújo Rodrigues

    This is really fascinating, You are a very skilled blogger. I've joined your feed and stay up for in the hunt for more of your fantastic post. Also, I have shared your website in my social networks|

  • Comment Link Lelio Vieira Carneiro Wednesday, 18 October 2017 11:04 posted by Lelio Vieira Carneiro

    Hi there are using Wordpress for your blog platform? I'm new to the blog world but I'm trying to get started and create my own. Do you require any html coding expertise to make your own blog? Any help would be greatly appreciated!|

  • Comment Link Eric Wednesday, 18 October 2017 11:04 posted by Eric

    John McEnroe and Joan Benoit put on our shoes on a regular basis, but
    it's not the contract.

  • Comment Link Milton Hoek Wednesday, 18 October 2017 11:01 posted by Milton Hoek

    I loved as much as you'll receive carried out right here. The sketch is attractive, your authored subject matter stylish. nonetheless, you command get bought an impatience over that you wish be delivering the following. unwell unquestionably come further formerly again as exactly the same nearly very often inside case you shield this increase.

  • Comment Link Tinisha Rudge Wednesday, 18 October 2017 11:01 posted by Tinisha Rudge

    I'm not sure why but this website is loading very slow for me. Is anyone else having this problem or is it a problem on my end? I'll check back later on and see if the problem still exists.

  • Comment Link Luiz Fernando Monteiro Bittencourt Wednesday, 18 October 2017 11:00 posted by Luiz Fernando Monteiro Bittencourt

    If you wish for to obtain a good deal from this article then you have to apply such techniques to your won weblog.|

  • Comment Link Hudson Wednesday, 18 October 2017 10:57 posted by Hudson

    Some really nice and useful info on this internet site, also I believe the pattern has wonderful features.

  • Comment Link Umanizzare Gestão Prisional Ltda Wednesday, 18 October 2017 10:56 posted by Umanizzare Gestão Prisional Ltda

    This piece of writing offers clear idea for the new people of blogging, that genuinely how to do running a blog.|

  • Comment Link Jodi Wednesday, 18 October 2017 10:55 posted by Jodi

    Haave you ever considered creating an e-book or guest authoring on othher blogs?
    I have a blog centered on thee szme subjects you discuss and wold love to haave you share some stories/information. I
    know mmy readers would enjoy your work. If you are even remotely interested, feel free to shoot
    me an e-mail.

Leave a comment

Make sure you enter the (*) required information where indicated. HTML code is not allowed.